Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK-8141

Known as: ACT-077825 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Background/Aims: The study objective was to investigate and compare the pharmacokinetics of a single oral dose of ACT-077825, a… Expand
  • figure 2
  • table 1
  • table 2
  • figure 3
  • table 3
2013
2013
Abstract: This study was conducted to characterize the multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT… Expand
2013
2013
This open‐label, randomized study evaluated the effects of steady‐state diltiazem on the pharmacokinetic, safety, and… Expand
2012
2012
PurposeTo evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of escalating single oral doses of ACT-077825… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2010
2010
The renin inhibitor MK-8141 (ACT-077825) demonstrates substantial immunoreactive active renin (ir-AR) increase (sevenfold… Expand
2009
2009
(+)-Dapoxetine hydrochloride; Abatacept, Adalimumab, Agalsidase beta, Alemtuzumab, Alglucosidase alfa, Aliskiren fumarate… Expand